Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Industry's Off-Label Hearing Priorities Taking Shape

Executive Summary

Pfizer attorney raises impact on research and other key themes for the upcoming FDA public hearing.


Related Content

Payers Want Access To US FDA's Pre-Submission Meetings
‘Who Is The Arbiter?’ US FDA Asks As It Mulls Loosening Off-Label Reins
FDA's Off-Label Communication Changes Should Start With Payers – PhRMA
Off-Label Debate Between FDA, Industry To Formally Begin After Election
Off-Label Communication Principles From PhRMA, BIO Aim For Reg Changes
Consumer-Focused Off-Label Promotion Seems Possible After Amarin Settlement


Related Companies